These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22290024)

  • 41. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
    Bełtowski J; Kedra A
    Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.
    Böger RH; Maas R; Schulze F; Schwedhelm E
    Clin Chem Lab Med; 2005; 43(10):1124-9. PubMed ID: 16197309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects.
    Schulze F; Maas R; Freese R; Schwedhelm E; Silberhorn E; Böger RH
    Eur J Clin Invest; 2005 Oct; 35(10):622-6. PubMed ID: 16178881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study.
    Engler MM; Engler MB; Malloy M; Chiu E; Besio D; Paul S; Stuehlinger M; Morrow J; Ridker P; Rifai N; Mietus-Snyder M
    Int J Clin Pharmacol Ther; 2004 Dec; 42(12):672-9. PubMed ID: 15624283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ADMA and oxidative stress.
    Sydow K; Münzel T
    Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
    Lin KY; Ito A; Asagami T; Tsao PS; Adimoolam S; Kimoto M; Tsuji H; Reaven GM; Cooke JP
    Circulation; 2002 Aug; 106(8):987-92. PubMed ID: 12186805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-body nitrogen and splanchnic amino acid metabolism differ in rats fed mixed diets containing casein or its corresponding amino acid mixture.
    Daenzer M; Petzke KJ; Bequette BJ; Metges CC
    J Nutr; 2001 Jul; 131(7):1965-72. PubMed ID: 11435515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension.
    Gorenflo M; Zheng C; Werle E; Fiehn W; Ulmer HE
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):489-92. PubMed ID: 11300662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997.
    Burgard P; Bremer HJ; Bührdel P; Clemens PC; Mönch E; Przyrembel H; Trefz FK; Ullrich K
    Eur J Pediatr; 1999 Jan; 158(1):46-54. PubMed ID: 9950308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiology and biochemistry of endothelial function in children with chronic renal failure.
    Kari JA; Donald AE; Vallance DT; Bruckdorfer KR; Leone A; Mullen MJ; Bunce T; Dorado B; Deanfield JE; Rees L
    Kidney Int; 1997 Aug; 52(2):468-72. PubMed ID: 9264003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utilisation of amino acid mixtures in adolescents with phenylketonuria.
    Mönch E; Herrmann ME; Brösicke H; Schöffer A; Keller M
    Eur J Pediatr; 1996 Jul; 155 Suppl 1():S115-20. PubMed ID: 8828625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU).
    Huemer M; Simma B; Mayr D; Möslinger D; Mühl A; Schmid I; Ulmer H; Bodamer OA
    J Inherit Metab Dis; 2012 Sep; 35(5):817-21. PubMed ID: 22290024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diet in children with phenylketonuria and risk of cardiovascular disease: A narrative overview.
    Verduci E; Banderali G; Moretti F; Lassandro C; Cefalo G; Radaelli G; Salvatici E; Giovannini M
    Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):171-7. PubMed ID: 26708644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal serum phenylalanine for adult patients with phenylketonuria.
    Okano Y; Nagasaka H
    Mol Genet Metab; 2013 Dec; 110(4):424-30. PubMed ID: 24094552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance.
    Teerlink T
    Clin Chem Lab Med; 2005; 43(10):1130-8. PubMed ID: 16197310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ADMA and hyperhomocysteinemia.
    Dayal S; Lentz SR
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.